BioLineRx

Historical price data

BioLineRx is a publicly traded, Israeli biotech company with a mission to develop best-in-class therapies for oncology and rare diseases. Its core strategy involves in-licensing and advancing novel drug candidates through clinical proof-of-concept, exemplified by the successful FDA approval and out-licensing of its stem cell mobilizer, motixafortide (APHEXDA®). The company has now pivoted back to a lean development model, focusing its resources on a promising new joint venture for GLIX1 in glioblastoma and a partnered Phase 2b trial in pancreatic cancer.

A proprietary drug development platform focused on the strategic in-licensing and integrated clinical advancement of novel therapeutic candidates through proof-of-concept, rather than a single scientific technology.

BioLineRx faces intense competition in both glioblastoma and pancreatic cancer from large pharma and biotech companies. Its differentiation lies in novel mechanisms (GLIX1's DNA damage response targeting) and a unique drug development model that has already proven capable of achieving FDA approval and strategic partnerships.